Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms

  title={Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms},
  author={Kateřina Venderov{\'a} and Ev{\vz}en Rů{\vz}i{\vc}ka and Viktor Voř{\'i}{\vs}ek and Peter Vi{\vs}ňovsk{\'y}},
  journal={Movement Disorders},
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit. © 2004 Movement Disorder Society 
Cannabis use in Parkinson’s disease—A nationwide online survey study
The aim of this study was to investigate the frequency of use, attitudes toward, and experiences with cannabis and cannabis‐related products among people with Parkinson's disease (PwP) living in
Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes Among Providers at National Parkinson Foundation Centers of Excellence
Legalization of the medical use of cannabis for Parkinson's disease (PD) has bypassed the traditional drug‐approval process, leaving physicians with little evidence with which to guide patients.
Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
The objective of this study was to assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in Parkinson's disease (PD).
Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study
The study suggests that cannabis might have a place in the therapeutic armamentarium of PD, with significant improvement of sleep and pain scores and no significant adverse effects of the drug were observed.
Pros and Cons of Marijuana in Treatment of Parkinson’s Disease
With medical marijuana gaining popularity and being legalized in the United States, the pros and cons of marijuana in the treatment of Parkinson’s disease are examined.
Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience
Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects in this pilot, 2-center, retrospective survey.
Cannabis in Parkinson's Disease - the patient's perspective versus clinical trials: a systematic literature review.
It is concluded that there is currently insufficient data to support the administration of cannabinoids to PD patients and larger, randomised studies of cannabis use in PD should be conducted.
Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis
No compelling evidence was found to recommend the use of cannabis in PD patients, but a potential benefit was identified with respect to alleviation of PD related tremor, anxiety, pain, improvement of sleep quality and quality of life.
Cannabinoids in the Treatment of Parkinson’s Disease
Experimental and clinical trials studying the effects of cannabinoids in idiopathic Parkinson’s disease are reviewed, finding only one trial found a reduction of levodopa-induced dyskinesia with cannabinoid treatment and the remaining trials showed no effect on Parkinsonian symptoms.
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy
The potential for cannabis to enhance the quality of life of Parkinson's patients is explored and the potential of medical marijuana and related compounds in the treatment of both motor and nonmotor symptoms as well as in slowing the progression of the disease.


The perceived effects of smoked cannabis on patients with multiple sclerosis.
The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.
Marijuana for parkinsonian tremor.
The results do not support the notion that cannabis when smoked reduces tremor or any other Parkinsonian disabilities and it may be that its non-specific sedative or anxiolytic actions benefit certain tremulous patients when anxiety is a significant trigger factor.
Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
  • J. Brotchie
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 1998
How non‐dopaminergic manipulations could reverse the abnormalities in basal ganglia circuitry responsible for generating dyskinesia is discussed and it is proposed that potential anti‐dyskinetic drugs might include glutamate (NMDA) receptor antagonists, opioid receptors antagonists, cannabinoid receptor agonists or antagonists, α2 adrenergic receptor antagonist, and 5‐HT‐enhancing agents.
Cannabis in Movement Disorders
There is evidence that cannabinoids are of therapeutic value in the treatment of tics in Tourette syndrome, the reduction of levodopa-induced dyskinesia in Parkinson''s disease and some forms of tremor and dystonia and it can be speculated that cannabinoid antagonists might be useful in thetreatment of chorea in Huntington''s Disease and hypokinetic parkinsonian syndromes.
Reflex blepharospasm associated with bilateral basal ganglia lesion
The findings in this patient support the notion that blepharospasm may be secondary to basal ganglia dysfunction through abnormal facilitation of reticular formation neurons controlling facial nucleus motoneuron excitability.
Decreased [18F]Spiperone Binding in Putamen in Idiopathic Focal Dystonia
Findings are consistent with a decrease of dopamine D2-like binding in putamen and are the first demonstration of a receptor abnormality in idiopathic dystonia, which has important implications for the pathophysiology of dySTONia as well as for function of the basal ganglia.
Stuttering and gait disturbance after supplementary motor area seizure
A patient who presented with both acquired stuttering and long‐lasting gait disturbance after SMA seizure is reported on.
Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Testing the hypothesis that the cannabinoid receptor agonist nabilone would alleviate levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride ‐lesioned marmoset model of Parkinson's disease found it to be useful in the treatment of motor complications in Parkinson’s disease.
CB1 cannabinoid receptor signalling in Parkinson's disease.
  • J. Brotchie
  • Biology, Medicine
    Current opinion in pharmacology
  • 2003